Last updated: September 3, 2026
Fosinopril sodium/hydrochlorothiazide is a mature, low-revenue antihypertensive combination that has largely transitioned from branded pharmaceutical product to generic commodity. The product combines the ACE inhibitor fosinopril with hydrochlorothiazide, a thiazide diuretic. Its commercial decline reflects loss of brand exclusivity, broad generic substitution, therapeutic competition from other fixed-dose combinations, and limited prescribing growth in a crowded hypertension market.
Public sources do not report a reliable standalone global revenue figure for fosinopril sodium/hydrochlorothiazide. The product is generally grouped within generic ACE inhibitor/thiazide markets, where sales are fragmented among manufacturers, wholesalers, pharmacy benefit managers, hospitals, and retail pharmacies.
What is fosinopril sodium and hydrochlorothiazide used for?
Fosinopril sodium/hydrochlorothiazide is an oral fixed-dose combination for hypertension. Fosinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation and aldosterone activity. Hydrochlorothiazide increases sodium and water excretion.
The combination is intended for patients who require more than one antihypertensive mechanism or who do not achieve adequate blood-pressure control with either component alone. The U.S. labeling identifies the product as a treatment for hypertension and generally positions it after dose titration with the individual components or when combination therapy is clinically appropriate.[1]
Typical strengths historically included:
| Strength |
Fosinopril sodium |
Hydrochlorothiazide |
| Low dose |
10 mg |
12.5 mg |
| Intermediate dose |
20 mg |
12.5 mg |
| Higher diuretic dose |
20 mg |
25 mg |
Exact marketed strengths and current availability vary by manufacturer and jurisdiction. The combination is available as tablets, not as an injectable or extended-release product.
How does the combination work clinically?
The two active ingredients provide complementary blood-pressure effects. Fosinopril suppresses the renin-angiotensin system, while hydrochlorothiazide reduces extracellular fluid volume. The combination can reduce the need for separate prescriptions, but its commercial relevance has weakened as newer fixed-dose products and alternative antihypertensive classes have expanded.
Important safety considerations include hypotension, renal impairment, hyperkalemia from fosinopril, hyponatremia and hypokalemia from hydrochlorothiazide, angioedema, and fetal toxicity. ACE inhibitors are contraindicated during pregnancy. Product labeling also warns against use with certain combinations involving aliskiren, particularly in patients with diabetes or renal impairment.[1]
What is the FDA regulatory status of fosinopril/hydrochlorothiazide?
The original branded product was marketed in the United States as Monopril HCT by Bristol-Myers Squibb. The product received FDA approval in the 1990s as a combination antihypertensive. The FDA’s Drugs@FDA database and product labeling establish the historical U.S. regulatory pathway and labeling record.[2]
The commercial status of the branded product has changed over time. Monopril HCT is no longer a major branded hypertension product, and current U.S. supply is associated primarily with generic versions or limited-distribution products. FDA product databases distinguish approval from current commercial marketing, so an approved application may remain in regulatory records even when the corresponding product is discontinued or commercially inactive.[2]
| Regulatory element |
Status |
| Active ingredients |
Fosinopril sodium and hydrochlorothiazide |
| Dosage form |
Oral tablet |
| Therapeutic category |
Antihypertensive |
| U.S. reference brand |
Monopril HCT |
| FDA pathway |
Small-molecule new drug application followed by generic abbreviated new drug applications |
| Current commercial profile |
Mature generic or limited-demand product |
| Biosimilar pathway |
Not applicable |
When did fosinopril/hydrochlorothiazide lose exclusivity?
The product lost meaningful commercial exclusivity after expiration of the patents and regulatory protections associated with fosinopril and the branded combination. Hydrochlorothiazide itself has been generic for decades and does not provide a meaningful exclusivity barrier.
Fosinopril was developed and commercialized in the 1980s and 1990s. Its core composition-of-matter and related pharmaceutical protections expired well before the current period. The combination therefore no longer has a conventional patent-based barrier to generic entry in the United States.
What patents protect fosinopril sodium/hydrochlorothiazide?
No commercially significant active U.S. patent estate is generally associated with the legacy Monopril HCT product today. Historical protection covered the fosinopril active ingredient, pharmaceutical compositions, and product development. Hydrochlorothiazide was already an established generic compound.
The key commercial conclusion is that the product’s patent estate is expired or otherwise no longer capable of supporting branded pricing. Any remaining patents in a particular jurisdiction would need to be assessed against the actual product, dosage, formulation, and patent register for that country.
| IP category |
Commercial assessment |
| Fosinopril composition patents |
Historical; expired |
| Hydrochlorothiazide composition patents |
Long expired |
| Fixed-dose combination patents |
Historical and not a current U.S. market barrier |
| New formulation patents |
No major differentiated formulation identified for the legacy product |
| Manufacturing patents |
Unlikely to prevent ordinary generic manufacture |
| Method-of-use patents |
No material current U.S. exclusivity identified |
| Trade secrets |
Possible at manufacturer level, but not a market-exclusion mechanism |
What is the Orange Book status of fosinopril/hydrochlorothiazide?
The Orange Book is relevant for determining reference-listed drug status, therapeutic equivalence, patents, and regulatory exclusivity. For an old small-molecule combination such as fosinopril/hydrochlorothiazide, the primary commercial issue is generic substitution rather than Orange Book patent enforcement.[3]
A product-specific Orange Book review should distinguish:
- The historical reference-listed product.
- Current abbreviated new drug applications.
- Any listed patents that remain unexpired.
- Therapeutic-equivalence ratings for approved generic tablets.
- Whether the branded application is currently marketed.
The product does not present the profile of a drug with active pediatric, orphan, new chemical entity, or major supplemental exclusivity. No current market thesis should rely on Orange Book protection for fosinopril/hydrochlorothiazide.
Which companies are challenging fosinopril/hydrochlorothiazide?
Generic competition is the dominant competitive force. Generic manufacturers of fosinopril/hydrochlorothiazide have historically included large and mid-sized U.S. generic suppliers, although the exact active supplier set changes as manufacturers discontinue low-volume products or consolidate portfolios.
Unlike a recently launched brand, the product is unlikely to face a commercially important wave of Paragraph IV challenges. Paragraph IV litigation is generally relevant when a generic applicant challenges an unexpired listed patent. For this mature combination, the main entry events occurred after original patent expiry, and current competition is more likely to involve ANDA approvals, supply decisions, and price bidding than patent litigation.
Are there current Paragraph IV risks?
Paragraph IV risk is low relative to products with active formulation or method-of-use patents. A new applicant could still make a certification against a listed patent if one existed, but the economic value of such a challenge would be limited unless the applicant could obtain substantial volume or a meaningful supply position.
The more material risks are:
- Product discontinuation by one or more suppliers.
- Manufacturing-site observations or remediation.
- Active-ingredient shortages.
- Loss of pharmacy distribution.
- Contract exclusion by major buyers.
- Price erosion after additional generic entry.
How strong is the patent estate for fosinopril sodium/hydrochlorothiazide?
The patent estate is weak from a present-day commercial perspective. The product has no evident patent-based pricing power, no active biologic exclusivity, and no differentiated delivery system that would materially restrict substitution.
Patent strength can be assessed across five dimensions:
| Dimension |
Assessment |
| Composition of matter |
Weak; historical protection expired |
| Combination product |
Weak; mature fixed-dose combination |
| Formulation |
Limited differentiation |
| Method of treatment |
Limited current exclusivity |
| Manufacturing process |
Potentially useful for cost control, but not market exclusion |
Manufacturing know-how can still affect gross margin. A producer with efficient sourcing, validated processes, reliable regulatory compliance, and low-cost packaging may outperform competitors even without enforceable product patents.
What is the financial trajectory of fosinopril/hydrochlorothiazide?
The financial trajectory is consistent with a late-stage generic product:
- Branded launch and physician adoption.
- Growth through combination therapy and brand detailing.
- Loss of patent protection.
- Generic entry and rapid price compression.
- Mature, fragmented demand.
- Low but recurring revenue for efficient manufacturers.
- Potential discontinuation if margins fall below manufacturing and regulatory costs.
Standalone revenue is not usually disclosed by public companies because fosinopril/hydrochlorothiazide is generally included within broader generic portfolios. Public filings typically report total generic pharmaceutical revenue rather than product-level sales for this molecule.
What determines current revenue?
Current revenue depends more on supply and contracting than on innovation. The main variables are:
- Prescription volume in hypertension.
- Number of active generic suppliers.
- Reimbursement rates.
- Retail and mail-order substitution.
- Wholesale acquisition cost and pharmacy reimbursement.
- Manufacturing cost of active pharmaceutical ingredients.
- Product availability in each strength.
- Hospital and payer formulary policies.
The combination’s low unit price limits absolute revenue potential. A manufacturer can generate recurring sales from stable demand, but the product is unlikely to become a material growth driver without a differentiated channel, shortage-driven pricing, or a bundled portfolio strategy.
How does the product compare with competing drugs?
| Product |
Market position |
Commercial assessment |
| Fosinopril/hydrochlorothiazide |
Mature ACE inhibitor/thiazide combination |
Low-price, low-growth generic |
| Lisinopril/hydrochlorothiazide |
Broadly prescribed ACE inhibitor/thiazide combination |
Stronger generic scale and demand |
| Enalapril/hydrochlorothiazide |
Established alternative |
Mature and price competitive |
| Losartan/hydrochlorothiazide |
ARB/thiazide combination |
Often preferred where cough or ACE intolerance matters |
| Valsartan/hydrochlorothiazide |
ARB/thiazide combination |
Competes through ARB use and branded history |
| Amlodipine/benazepril |
Calcium-channel blocker/ACE inhibitor |
Different mechanism and patient segment |
Lisinopril/hydrochlorothiazide has a larger installed base and stronger generic recognition in many markets. Losartan/hydrochlorothiazide competes directly for patients who require renin-angiotensin system blockade but do not tolerate ACE inhibitors.
What generic entry risks exist for fosinopril/hydrochlorothiazide?
Generic entry risk is already realized rather than prospective. The principal risk to any remaining branded or authorized-generic revenue is continued price erosion and substitution.
For generic manufacturers, the risk profile is different. Entry may be technically straightforward, but commercial returns can be poor because:
- Several suppliers may already be approved.
- Pharmacy buyers may prefer larger portfolios.
- The product has limited promotional demand.
- Low prices leave little margin for manufacturing deviations.
- Small volume can make multiple strengths uneconomic.
- Regulatory maintenance costs persist even after prices decline.
A new entrant would generally need a cost advantage, reliable supply, an established distribution network, or a portfolio strategy to justify development.
What formulation and manufacturing barriers remain?
The tablets do not appear to depend on a novel delivery platform. The principal technical requirements are conventional solid-dose manufacturing, assay and impurity control, content uniformity, dissolution, stability, packaging, and bioequivalence.
Manufacturing barriers can still arise from:
- Fosinopril active-ingredient sourcing.
- Hydrochlorothiazide supply consistency.
- Moisture and stability controls.
- Separate management of low-dose hydrochlorothiazide content.
- Validated analytical methods.
- Scale economics for multiple strengths.
- FDA inspection and data-integrity requirements.
These barriers influence the number of reliable suppliers but do not create meaningful patent exclusivity.
Does fosinopril/hydrochlorothiazide have biosimilar risk?
No. Biosimilars apply to biologic products, while fosinopril sodium/hydrochlorothiazide is a chemically synthesized small-molecule tablet. Competition occurs through the generic drug pathway, primarily abbreviated new drug applications in the United States and equivalent national procedures elsewhere.
What licensing deals affect fosinopril/hydrochlorothiazide?
No major current licensing transaction is central to the product’s market value. The original branded product was associated with Bristol-Myers Squibb’s commercialization of fosinopril. At present, any licensing economics are more likely to involve generic product rights, contract manufacturing, authorized-generic arrangements, or regional distribution agreements.
Such agreements can preserve access in smaller markets, but they generally do not restore the pricing power associated with active patent protection.
What is the geographic market outlook?
The product’s commercial status varies by jurisdiction. In the United States, generic substitution and mature ACE inhibitor use dominate. In Europe and other developed markets, reimbursement tenders and national formularies can reduce prices further. In emerging markets, fixed-dose antihypertensive combinations may retain demand because they simplify treatment and distribution.
Geographic opportunity is constrained by:
- Local registration requirements.
- Country-specific combination-product approvals.
- National reimbursement policies.
- Local manufacturing preferences.
- Tender pricing.
- Availability of competing ACE inhibitor and ARB combinations.
A regional supplier may find value in markets where the product remains registered but has limited competition. That opportunity is operational rather than patent-driven.
What is the outlook for investors and generic manufacturers?
Fosinopril sodium/hydrochlorothiazide is a defensive, low-growth product rather than an innovation or exclusivity asset. Its investment value depends on manufacturing efficiency, supply reliability, portfolio scale, and contractual access to buyers.
The most likely scenarios are:
| Scenario |
Probability profile |
Financial effect |
| Stable generic demand |
Base case |
Recurring but modest revenue |
| Further supplier exits |
Upside for remaining suppliers |
Temporary volume or price improvement |
| New low-cost entrant |
Downside |
Additional price erosion |
| Supply disruption |
Short-term upside or downside |
Volatile availability and margin |
| Brand relaunch |
Low probability |
Limited without differentiation |
| New formulation development |
Low probability |
Development cost may exceed market opportunity |
The product is unlikely to support a significant licensing premium, patent transaction, or strategic acquisition on a standalone basis. It may have portfolio value for a company with existing hypertension distribution, API procurement, or contract-manufacturing infrastructure.
Key Takeaways
- Fosinopril sodium/hydrochlorothiazide is a mature fixed-dose antihypertensive combination.
- Monopril HCT established the branded market, but current economics are predominantly generic.
- Historical fosinopril and combination-product protections no longer provide meaningful U.S. exclusivity.
- Orange Book and Paragraph IV issues are secondary to price competition, supply reliability, and reimbursement.
- The product has no biosimilar risk because it is a small-molecule drug.
- Standalone revenue is not normally disclosed and is likely modest relative to major antihypertensive combinations.
- Lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide are stronger commercial competitors.
- Manufacturing efficiency and distribution access matter more than patent ownership.
- The product may produce stable portfolio revenue but has limited growth or strategic premium potential.
FAQs
Is fosinopril/hydrochlorothiazide still commercially available?
Availability depends on country, dosage strength, and supplier. The branded product is no longer a major commercial franchise, while generic availability can change as manufacturers discontinue or relaunch individual strengths.
Can a company obtain market exclusivity by reformulating fosinopril/hydrochlorothiazide?
A genuinely differentiated formulation could potentially qualify for new patent protection, but regulatory approval and commercial value would depend on clinical or adherence benefits. A minor excipient change would not necessarily create meaningful market exclusivity.
Is fosinopril/hydrochlorothiazide included in hypertension treatment guidelines?
Guidelines generally support combination antihypertensive therapy when clinically appropriate, but they do not necessarily prioritize this specific ACE inhibitor/thiazide combination. Treatment selection depends on blood-pressure severity, comorbidities, tolerability, renal function, and local prescribing practice.[4]
What would cause a sudden price increase for this generic?
The most likely causes are supplier exits, active-ingredient shortages, manufacturing disruptions, product recalls, or wholesaler inventory constraints. A patent event is unlikely to be the cause.
Is the product attractive for contract manufacturing?
It may be attractive as part of a broader generic hypertension portfolio where shared sourcing, packaging, quality systems, and distribution reduce unit costs. As a standalone contract-manufacturing opportunity, its low price and limited volume reduce expected returns.
References
-
DailyMed. (n.d.). Fosinopril sodium and hydrochlorothiazide tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
